Ultrasound renal denervation (uRDN) was demonstrated to lower ambulatory systolic blood pressure (BP) versus a sham procedure at 2 months post-intervention in patients with mild to moderate hypertension (HTN)12 and resistant HTN3. While background medications were strictly controlled in these randomised studies, it is important to demonstrate the BP-lowering effect of uRDN in patients treated with antihypertensive medications (AHMs) prescribed by clinicians under unblinded conditions, reflecting a “real-world” setting.
The current analysis included pooled data from the 3 international, multicentre, randomised sham-controlled trials of the RADIANCE123 programme (ClinicalTrials.gov: NCT02649426 and NCT03614260), which compared changes in BP in patients with HTN who received either uRDN or a sham procedure. A list of the study investigators and lead coordinators can be found in Supplementary Appendix 1. All 3 studies required patients to be between 18 and 75 years of age, to have an estimated glomerular filtration rate (eGFR) of ≥40 mL/min/1.73 m2, and a suitable renal artery anatomy. The trials included patients with mild to moderate HTN on 0-2 AHMs12 or patients with...
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
